Arca
Skip to content

Acute myelogenous leukemia

Drug research and approvals for acute myelogenous leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 607 studies of acute myelogenous leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 23 drug trials for it since 2013, and FDA has 4 approved and 18 open orphan designations naming it.

  • Recruiting worldwide: 607
  • Trials authorized in Canada: 23
  • FDA orphan approvals: 4
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 607 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 23; search them all in Canada trials
Apr 24, 2023A phase 1/2 first in human study of the menin-mll (kmt2a) inhibitor ko 539 in patients with relapsed or refractory acute myeloid leukemiaZIFTOMENIB (KO-539)Kura OncologyOngoing
Aug 26, 2021A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of entospletinib in combination with intensive induction and…ENTOSPLETINIB (GS-9973)KRONOS BIO, INC.Ongoing
May 7, 2018A phase 3, randomized, controlled, open-label, clinical study of pevonedistat plus azacitidine versus single-agent azacitidine as first-line treatment for…PEVONEDISTAT (MLN4924) / AZACITIDINETakeda Pharmaceuticals USAOngoing
Aug 9, 2017A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ag-120 in combination with azacitidine in subjects ¿18 years of age with…IVOSIDENIB (AG-120)ServierClosed
Aug 16, 2016A phase I study of volasertib combined with standard induction chemotherapy for previously untreated patients with acute myeloid leukemia (viac)VOLASERTIBGOVERNORS OF THE UNIVERSITY OF ALBERTAPending
Jul 25, 2016A phase 1b/2 open-label, randomized study of 2 combinations of isocitrate dehydrogenase (idh) mutant targeted therapies plus azacitidine: oral ag-120 plus…ENASIDENIB (AG-221)/ IVOSIDENIB (AG-120)Bristol-Myers SquibbClosed
Mar 31, 2016A phase 3, multicenter, open-label, randomized study comparing the efficacy and safety of ag-221 (cc-90007) versus conventional care regimens in older subjects…ENASIDENIB (AG-221)/ AZACITIDINEBristol-Myers SquibbOngoing
Feb 26, 2016A randomized multicenter, open-label, phase 2 study evaluating the efficacy and safety of azacitidine subcutaneous in combination with durvalumab (medi4736) in…VIDAZA (AZACITIDINE)/ DURVALUMABBristol-Myers SquibbClosed
Feb 8, 2016A phase 2, randomized, controlled, open-label, clinical study of the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in…PEVONEDISTAT / AZACITIDINETakeda Pharmaceuticals USAClosed
Jan 7, 2016Phase I study of autologous acute myelogenous leukemia (aml) cells containing lentivirus engineering expression of il-12AUTOLOGOUS AML CELLS EXPRESSING IL-12UNIVERSITY HEALTH NETWORKOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 22
Aug 1, 2017IdhifaTreatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as…Celgene CorporationApproved
Sep 15, 1995LeukineFollowing induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to…Immunex CorporationApproved
Sep 27, 1990IdamycinTreatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.Adria Laboratories, Inc.Approved
Dec 23, 1987NovantroneTreatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.Lederle LaboratoriesApproved
Oct 17, 2025recombinant fusion protein composed of a high affinity MHC…treatment of acute myelogenous leukemiaLeukogene Therapeutics, Inc.Designated
Nov 26, 2019Recombinant Bispecific antibody targeting CD123 and CD3Treatment of acute myelogenous leukemiaAptevo Research and DevelopmentDesignated
Aug 21, 2019TalabostatTreatment of acute myelogenous leukemiaBioXcel Therapeutics, Inc.Designated
Nov 25, 2014225Ac-lintuzumabTreatment of acute myelogenous leukemiaActinium Pharmaceuticals, Inc.Designated
Mar 27, 2014LaromustineTreatment of acute myelogenous leukemiaNanoSHIFT LLCDesignated
Nov 19, 2012combretastatin A 1 diphosphateTreatment of acute myelogenous leukemiaMateon Therapeutics, Inc.Designated
Oct 31, 2012crenolanibTreatment of acute myelogenous leukemiaAROG Pharmaceuticals, LLCDesignated
Feb 4, 2011D-peptideTreatment of acute myelogenous leukemiaImmune System Key, LtdDesignated
Feb 4, 2011MLN4924-Inhibitor of Nedd8-activating enzyme (NAE)Treatment of acute myelogenous leukemia.Takeda Development Center Americas, Inc.Designated
Jun 24, 20101-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoy…Treatment of acute myelogenous leukemiaCyclacel LimitedDesignated
Oct 21, 2004laromustineTreatment of acute myelogenous leukemiaVion Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.